- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04613375
PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
April 18, 2024 updated by: Pfizer
Low Intervention Study of the Effectiveness Of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Against Vaccine Type Pneumococcal Hospitalised Community Acquired Pneumonia (CAP) in Adults 60 Years and Older Using A Test Negative Design Study in A Well-Defined Area of the South of Madrid Region
Low interventional, prospective, multicentre, hospital-based study involving adults 60 years of age and older hospitalised with CAP at participating sites.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
PCV13 efficacy for the prevention of vaccine-type community-acquired pneumonia (VT-CAP) and invasive pneumococcal disease (IPD) was established in the Community-acquired Pneumonia Immunization Trial in Adults (CAPITA) aged 65 and older.
However, there are still few available real-life effectiveness estimates in adults.
The aim of this study is to evaluate the PCV13 vaccine effectiveness (VE) against hospitalised VT-pneumococcal CAP among adults aged ≥60 years in the Region of Madrid (Spain).
Determination of the effectiveness of PCV13 to prevent hospitalised vaccine-type (VT)-pneumococcal CAP among adults aged ≥60 years in Madrid will be evaluated using a test-negative design study, overall and among immunocompetent persons only.
Study Type
Observational
Enrollment (Actual)
1786
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Alcorcón, Madrid, Spain, 28922
- Hospital Universitario Fundacion Alcorcon
-
Mostoles, Spain, 28935
- Hospital Universitario de Móstoles / Servicio de Oncología Médica
-
Móstoles, Spain, 28933
- Hospital Universitario Rey Juan carlos
-
-
Madrid
-
Getafe, Madrid, Spain, 28905
- Hospital Universitarios De Getafe
-
Leganés, Madrid, Spain, 28911
- Hospital Universitario Severo Ochoa
-
Mostoles, Madrid, Spain, 28935
- Hospital Universitario de Mostoles
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adults, aged 60 years and over, who are hospitalized with CAP in one of the study hospitals: Hospital Universitario de Móstoles, Hospital Universitario Fundación de Alcorcón, and Hospital Rey Juan Carlos de Móstoles.
Description
Inclusion Criteria:
- Age ≥60 years.
- Evidence of pneumonia within first 48 hours of hospital admission
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion Criteria:
- Any patient who develops signs and symptoms of pneumonia after being hospitalized for ≥48 hours (either at current hospital, another transferring hospital, or a combination of these).
- Previously enrolled subjects readmitted ≤14 days after discharge for their study qualifying admission.
- At the time of enrollment, pneumonia has been excluded as the diagnosis or another diagnosis confirmed.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
All participants
|
Serotype specific UAD (urinary antigen detection) test
Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaccine effectiveness (VE)
Time Frame: 4 years
|
VE calculated as 1 minus the OR* comparing the odds of having received PCV13 for cases and controls, multiplied by 100, overall and restricted to immunocompetent subjects only.
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of CAP events for each pneumococcal serotype, PCV-13, and 20-valent pneumococcal conjugate vaccine (PCV20) serotypes among all CAP subjects with UAD1/2 testing (overall) and among all CAP subjects with a pneumococcus identified
Time Frame: 4 years
|
Distribution of S. pneumoniae serotypes using blood, high-quality respiratory cultures, and a serotype-specific urinary antigen detection (UAD) assay among adults 60 years of age and older with CAP.
|
4 years
|
Proportion of persons with respiratory pneumococcal carriage among adults 60 years of age and older presenting with CAP
Time Frame: 4 years
|
Proportion of CAP events where the pneumococcus was identified from saliva by the conventional culture or the sensitive molecular method of PCR divided by all CAP events where the subject had a valid saliva specimen test result.
|
4 years
|
Proportion of participants with CAP and SP-CAP with underlying medical conditions
Time Frame: 4 years
|
Proportion of CAP subjects with underlying at-risk and high-risk medical conditions, overall and restricted to those with pneumococcus isolated from blood, high-quality respiratory cultures, and a serotype specific urinary antigen detection (UAD) assay
|
4 years
|
Frequency of antibiotic resistance among Streptococcus pneumoniae isolates by type
Time Frame: 4 years
|
Proportion of S. pneumoniae isolates with antibiotic resistance identified by standard of care testing, overall and by resistance type
|
4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 12, 2021
Primary Completion (Actual)
October 25, 2023
Study Completion (Actual)
March 24, 2024
Study Registration Dates
First Submitted
October 19, 2020
First Submitted That Met QC Criteria
November 2, 2020
First Posted (Actual)
November 3, 2020
Study Record Updates
Last Update Posted (Actual)
April 19, 2024
Last Update Submitted That Met QC Criteria
April 18, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B1851202
- CIBELES (Other Identifier: Alias Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Community Acquired Pneumonia (CAP)
-
PfizerCompletedCommunity-Acquired Pneumonia (CAP)United States, Canada, Germany, Greece, Spain
-
Fundacio d'Investigacio en Atencio Primaria Jordi...TerminatedCommunity-acquired Pneumonia (CAP)Spain
-
Melinta Therapeutics, Inc.CompletedCommunity-Acquired Pneumonia (CAP)Canada, United States, Russian Federation
-
PfizerCompletedCommunity Acquired Pneumonia (CAP)Japan
-
Basilea PharmaceuticaCompletedCommunity-acquired Pneumonia (CAP) | Hospital-acquired Pneumonia (HAP)Bulgaria, Hungary, Georgia, Romania
-
SanofiCompletedCommunity Acquired Pneumonia (CAP) | Acute Exacerbation of Chronic Bronchitis (AECB)
-
AbbottCompletedBronchitis | Chronic Bronchitis | Tracheobronchitis | Community-Acquired Pneumonia (CAP) | TracheitisCzech Republic
-
GlaxoSmithKlineTerminated
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineTerminated
Clinical Trials on Urine sample collection
-
Institut PasteurCentre Médical de l'Institut PasteurRecruiting
-
Changhai HospitalRenJi Hospital; Tongji Hospital; First Affiliated Hospital Xi'an Jiaotong University and other collaboratorsNot yet recruitingUrothelial Carcinoma | HematuriaChina
-
SPD Development Company LimitedCompleted
-
Unity Health TorontoCompleted
-
GlaxoSmithKlineCompleted
-
Masonic Cancer Center, University of MinnesotaCompletedAcute Leukemia | Chemotherapy-Induced Gut Barrier DamageUnited States
-
Kevin BruceNot yet recruiting
-
IRCCS San RaffaeleUniversità Vita-Salute San RaffaeleRecruitingCarcinoma, Renal Cell | Von Hippel-Lindau DiseaseItaly
-
Benjamin GesundheitShaare Zedek Medical CenterRecruiting
-
Medical University of ViennaCompletedFemale Stress Urinary IncontinenceAustria